Literature DB >> 16774458

Consequences of neuropathic pain: quality-of-life issues and associated costs.

Bill H McCarberg1, Richard Billington.   

Abstract

Pain is the primary reason for patients seeking healthcare, and it has been estimated to result in more than dollar 100 billion per year in direct medical costs. Neuropathic pain (NP) alone has been associated with an approximately 3-fold increase in use of healthcare resources. The indirect costs associated with chronic pain result from increased absenteeism and decreased productivity at work, and they also have been estimated to total dollar 100 billion each year in the United States. NP contributes substantially to these costs. Results from one study indicated that employment was affected in 43% of patients with NP. Quality of life is also significantly reduced in such patients. Patients with chronic pain also have difficulty in initiating and maintaining sleep, and sleep deprivation has the potential to exacerbate pain. Sleep deprivation is also associated with both anxiety and depression, and both of these conditions can exacerbate sleep disturbances. Effective management of the patient with chronic pain, including NP, requires assessment and, if necessary, treatment of all comorbidities associated with this condition.

Entities:  

Mesh:

Year:  2006        PMID: 16774458

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  43 in total

1.  Treating painful diabetic polyneuropathy.

Authors:  Edward B Jude; Nicolaas Schaper
Journal:  BMJ       Date:  2007-07-14

Review 2.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 3.  In search of analgesia: emerging roles of GPCRs in pain.

Authors:  Laura S Stone; Derek C Molliver
Journal:  Mol Interv       Date:  2009-10

4.  Chronic pain and cigarette smoking and nicotine dependence among a representative sample of adults.

Authors:  Michael J Zvolensky; Katherine McMillan; Adam Gonzalez; Gordon J G Asmundson
Journal:  Nicotine Tob Res       Date:  2009-10-14       Impact factor: 4.244

Review 5.  Neuroplasticity of ascending and descending pathways after somatosensory system injury: reviewing knowledge to identify neuropathic pain therapeutic targets.

Authors:  P Boadas-Vaello; S Castany; J Homs; B Álvarez-Pérez; M Deulofeu; E Verdú
Journal:  Spinal Cord       Date:  2016-01-12       Impact factor: 2.772

6.  Neuropathic pain's biopsychosocial effects.

Authors:  Esra Dogru Huzmeli; Ismet Melek
Journal:  Neurol Sci       Date:  2017-08-19       Impact factor: 3.307

Review 7.  Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain.

Authors:  Samuel D Banister; Kaavya Krishna Kumar; Vineet Kumar; Brian K Kobilka; Sanjay V Malhotra
Journal:  Medchemcomm       Date:  2019-03-18       Impact factor: 3.597

Review 8.  Corneal pain and experimental model development.

Authors:  Tina B McKay; Yashar Seyed-Razavi; Chiara E Ghezzi; Gabriela Dieckmann; Thomas J F Nieland; Dana M Cairns; Rachel E Pollard; Pedram Hamrah; David L Kaplan
Journal:  Prog Retin Eye Res       Date:  2018-11-16       Impact factor: 21.198

Review 9.  Potential role of nitric oxide synthase isoforms in pathophysiology of neuropathic pain.

Authors:  Abhilasha Ahlawat; Ajay Rana; Nidhi Goyal; Saurabh Sharma
Journal:  Inflammopharmacology       Date:  2014-08-06       Impact factor: 4.473

10.  Challenges in using opioids to treat pain in persons with substance use disorders.

Authors:  Seddon R Savage; Kenneth L Kirsh; Steven D Passik
Journal:  Addict Sci Clin Pract       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.